An observational study in E Cigarette Use, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Western University, Canada · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Vaping with a site in Canada — 6 open to participants now, 8 under way, 1 of them phase 3. Vaping · Canada.
Among the 13 studies in Vaping with a site in Canada, this one is one of 3 that started in 2023, is one of 3 observational ones, and was the 4th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →6 of the 13 studies in Vaping with a site in Canada are open now. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of British Columbia · Sites in Canada
Ages 12+ · Healthy volunteers
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 18+ · Healthy volunteers
University of Alberta · Sites in Canada
Ages 12–40 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 150 is above the median of 120 across 65 observational studies indexed under Vaping.
Median enrollment 155 across the 10 interventional studies, 250 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.
Western University, Canada has 1 study filed under Vaping — fewer than ten, so there is no comparison to draw.
1 of the studies in Vaping with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06164678Ottawa Heart Institute Research CorporationVaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Vaping with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a longitudinal study of the long-term health impact of e-cigarette smoking on the lungs. Participants will be followed over a period of 5 years, and impacts of e-cigarette smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.
This is a 5-year longitudinal study of the long-term lung health impact of e-cigarette smoking. Participants with a history of e-cigarette smoking age ≥ 16 years will be recruited from within 2 hours of London, ON through local family and tertiary care physicians, emergency departments and community and social media advertisements. Asymptomatic age and sex-matched participants who have never smoked e- or c-cigarettes will be recruited through community advertisement, media and social media. Participants must satisfy all inclusion and exclusion criteria in order to participate in the study. We will compare lung health of participants at baseline, 12 weeks, 24 weeks and 48 weeks, 3 years, 4 years and 5 years with an asymptomatic control group with no history of e-cigarette or c-cigarette use. The study will involve 6 in-person visits and 1 telephone call for a health update. All measurements will be made with at least 4 hours after the last cigarette and/or vape to provide a way to practically focus on chronic and not acute effects. Pulmonary function and imaging measurements will be made before and after bronchodilator administration.
At Visit 1, informed consent will be obtained before any study related assessments or procedures are performed. Eligibility criteria will be reviewed. Safety assessments including vital signs, pulmonary function testing, hematology, sputum sampling, exercise testing, and respiratory questionnaires will be completed.
Visit 2 will take place 12 weeks after visit 1 and will include vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, chest CT scan, exercise testing, and questionnaires.
Visit 3 will take place at 24 weeks and will involve a telephone call to update health information as well as questionnaires.
Visit 4 will take place at 48 weeks and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, hematology, blood chemistry, sputum analysis, exercise testing, and questionnaires.
Visit 5 will take place at year 3 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.
Visit 6 will take place at year 4 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.
Visit 7 will take place at year 5 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires
Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires
Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires
Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
Also known as: 129Xe MRI
Participants will undergo a CT scan of the thoracic cavity
Also known as: CT
Participants will have their lung function evaluated using PFT
Also known as: PFT
Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
Also known as: CPET
Participants will provide a sputum sample that will be analysed for eosinophils
Participants will have their blood drawn and analysed for eosinophil count.
Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report pulmonary imaging abnormalities.
Measured using 129-Xe MRI
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report pulmonary imaging abnormalities.
Measured using computed tomography imaging
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FEV1.
Measured using forced expiratory volume in one second (FEV1)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FVC.
Measured using forced vital capacity (FVC)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by TLC.
Measured using total lung capacity (TLC)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FRC.
Measured using functional residual capacity (FRC)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by RV.
Measured using residual volume (RV)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FOT.
Measured using forced oscillation technique (FOT)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by LCI.
Measured using lung clearance index (LCI)
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FeNO.
Measured using Fractional Exhaled Nitric Oxide (FeNO).
Time frame: 12 weeks following enrollment
Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by exercise capacity
Exercise capacity measured by cardio-pulmonary exercise testing (CPET)
Time frame: 12 weeks following enrollment
Differences in airways between e-cigarette-only smokers and both e-cigarette and c-cigarette smokers.
Measured using 129-Xe MRI
Time frame: 5 years
Differences in airways between e-cigarette-only smokers and never smokers.
Measured using 129-Xe MRI
Time frame: 5 years
Differences in parenchyma between e-cigarette-only smokers and both e-cigarette and c-cigarette smokers.
Measured using 129-Xe MRI
Time frame: 5 years
Differences in parenchyma between e-cigarette-only smokers and never smokers.
Measured using 129-Xe MRI
Time frame: 5 years
Changes in airways of e-cigarette smokers over time.
Measured using Xenon-129 (129-Xe) MRI
Time frame: 5 years
Changes in parenchyma of e-cigarette smokers over time.
Measured using Xenon-129 (129-Xe) MRI
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by FEV1.
Measured using forced expiratory volume in one second (FEV1).
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by FVC.
Measured using forced vital capacity (FVC)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by TLC.
Measured using total lung capacity (TLC)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by FRC.
Measured using functional residual capacity (FRC)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by RV.
Measured using residual volume (RV)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by FOT.
Measured using forced oscillation technique (FOT).
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by LCI.
Measured using lung clearance index (LCI)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by FeNO.
Measured using Fractional Exhaled Nitric Oxide (FeNO)
Time frame: 5 years
Changes in lung function of e-cigarette smokers over time as measured by exercise capacity.
Exercise capacity measured by cardio-pulmonary exercise testing (CPET)
Time frame: 5 years
Changes in lung health of e-cigarette smokers over time as measured by the mMRC dyspnea scale questionnaire.
Measured using the modified medical research council (mMRC) dyspnea scale
Time frame: 5 years
Changes in lung health of e-cigarette smokers over time as measured by SGRQ.
Measured using the St. George's respiratory questionnaire (SGRQ)
Time frame: 5 years
Changes in lung health of e-cigarette smokers over time as measured by CAT.
Measured using the COPD assessment test (CAT)
Time frame: 5 years
Changes in lung health of e-cigarette smokers over time as measured by IPAQ.
Measured using the International Physical Activity Questionnaire (IPAQ).
Time frame: 5 years
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
Of 32 observational studies under Vaping, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 46. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.